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Abstract
Alzheimer's	disease	(AD)	is	an	age-related	neurodegenerative	disease.	The	most	com-
mon pathological hallmarks are amyloid plaques and neurofibrillary tangles in the 
brain.	In	the	brains	of	patients	with	AD,	pathological	tau	is	abnormally	accumulated	
causing	neuronal	loss,	synaptic	dysfunction,	and	cognitive	decline.	We	found	a	his-
tone	deacetylase	6	(HDAC6)	inhibitor,	CKD-504,	changed	the	tau	interactome	dra-
matically	to	degrade	pathological	tau	not	only	in	AD	animal	model	(ADLPAPT)	brains	
containing	both	amyloid	plaques	and	neurofibrillary	tangles	but	also	in	AD	patient-
derived	brain	organoids.	Acetylated	tau	recruited	chaperone	proteins	such	as	Hsp40,	
Hsp70,	and	Hsp110,	and	this	complex	bound	to	novel	tau	E3	ligases	including	UBE2O	
and	RNF14.	This	complex	degraded	pathological	tau	through	proteasomal	pathway.	
We	also	identified	the	responsible	acetylation	sites	on	tau.	These	dramatic	tau-inter-
actome changes may result in tau degradation, leading to the recovery of synaptic 
pathology	and	cognitive	decline	in	the	ADLPAPT mice.
K E Y W O R D S
Alzheimer's	disease,	neurodegenerative	diseases,	tau,	tau	interactome,	tau	post-translational	
modification
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1  | INTRODUC TION
Alzheimer's	 disease	 (AD)	 is	 the	 most	 common	 neurodegenera-
tive	 disease	 that	 causes	 dementia.	 Intracellular	 accumulation	 of	
pathological	 tau	 proteins	 as	 neurofibrillary	 tangles	 (NFTs)	 and	
extracellular	accumulation	of	beta-amyloid	 (Aβ)	as	senile	plaques	
are	 the	major	 pathological	 features	 of	AD	 (Querfurth	&	 LaFerla,	
2010).	Physiologically,	tau	regulates	microtubule	dynamics	(Qiang	
et	al.,	2018),	whereas	pathologically,	tau	is	highly	phosphorylated	
and	aggregates	 to	 form	NFTs	 in	AD	 (Wang	&	Mandelkow,	2016).	
Hyperphosphorylated and aggregated tau leads to synapse dys-
function,	mitochondrial	damage,	and	neuronal	cell	death	 (Shafiei,	
Guerrero-Munoz,	&	Castillo-Carranza,	2017;	Wang	&	Mandelkow,	
2016).	 Accumulated	 tau,	 rather	 than	 amyloid	 plaques,	 is	 more	
correlated	with	cognitive	decline	in	patients	with	AD	(Brier	et	al.,	
2016).	Several	recent	studies	have	reported	that	reducing	endog-
enous	tau	attenuates	 the	manifestations	of	Aβ toxicity, including 
deficits	 in	 axonal	 transport,	 seizures,	 cognitive	 impairment,	 and	
decreased survival, indicating that tau acts as an effector mole-
cule	 to	mediate	Aβ	 toxicity	 (Roberson	 et	 al.,	 2007;	Vossel	 et	 al.,	
2010).	 In	 addition,	 numerous	 clinical	 trials	 of	 therapeutic	 strate-
gies	targeting	Aβ	have	failed	(Anderson,	Hadjichrysanthou,	Evans,	
&	Wong,	 2017);	 thus,	 other	 therapies	 having	 nonamyloid	mech-
anisms	 of	 action,	 especially	 tau-related	 targets,	 are	 active	 areas	
of	 early-stage	 drug-development	 efforts	 (Cummings,	 Lee,	 Ritter,	
&	 Zhong,	 2018).	 Therefore,	 reducing	 tau	 could	 be	 a	 prospective	
strategy	for	treating	AD.
In	 AD,	 post-translational	 modifications	 (PTMs)	 are	 largely	
changed	(Marcelli	et	al.,	2018).	Acetylation	is	one	of	the	important	
PTMs	 that	has	a	variety	of	biological	 roles	 such	as	histone	modu-
lation,	 metabolism,	 and	 stress	 response.	 Histone	 deacetylase	 6	
(HDAC6),	which	 is	unique	among	histone	deacetylases	because	of	
its primary cytosolic location, deacetylates several cytosolic pro-
teins, including α-tubulin	and	tau	(Cook	et	al.,	2014;	Li,	Shin,	&	Kwon,	
2013).	HDAC6	is	increased	in	the	brains	of	patients	with	AD	(Ding,	
Dolan,	&	Johnson,	2008),	suggesting	that	targeting	HDAC6	could	be	
a	potential	therapeutic	strategy	in	AD.	Indeed,	reducing	or	inhibiting	
HDAC6	has	been	shown	to	attenuate	cognitive	deficits,	decrease	Aβ 
plaques	in	AβPPswe/PS1ΔE9 mice, and ameliorate tau pathologies in 
rTg4510	mice	as	well	as	primary	cultured	neurons	(Cook	et	al.,	2014;	
Tseng	et	al.,	2017;	Zhang	et	al.,	2014).	In	addition,	it	is	reported	that	
acetylation	of	tau	at	several	HDAC6-regulated	sites	competes	with	
phosphorylation	of	tau	and	thus	inhibits	its	aggregation	(Carlomagno	
et	al.,	2017;	Cook	et	al.,	2014).	HDAC6	also	plays	an	important	role	
in	the	ubiquitin–proteasome	system	(UPS)	and	autophagy–lysosome	
system	(ALS)	(Van	Helleputte,	Benoy,	&	Van	Den	Bosch,	2014),	both	
of	which	are	known	to	be	responsible	for	tau	degradation	(Lee,	Lee,	
&	Rubinsztein,	2013).	Because	 tau	 is	a	 substrate	of	HDAC6	 (Cook	
et	al.,	2014),	HDAC6	might	regulate	tau	degradation.	However,	the	
specific	mechanism	by	which	HDAC6	inhibition	causes	tau	degrada-
tion	in	AD	is	not	yet	known.	Moreover,	to	our	knowledge,	there	has	
been	little	or	no	investigation	of	the	therapeutic	effects	of	HDAC6	
inhibition	on	human	brain	organoids	or	AD	model	animals	exhibiting	
both	Aβ and tau pathologies.
Here,	 we	 investigated	 the	 therapeutic	 effects	 of	 CKD-504,	
which	 is	 a	 novel,	 selective,	 and	 highly	 blood–brain	 barrier	 (BBB)-
penetrating	HDAC6	inhibitor.	CKD-504	effectively	modified	acetyl-
ation	 both	 in	 brain	 organoids	 formed	 from	 AD	 patient-derived	
induced	 pluripotent	 stem	 cells	 (iPSCs)	 and	 ADLPAPT	 (Alzheimer's	
disease-like	pathologyAPP	&	Tau)	mice	exhibiting	both	Aβ and tau pa-
thologies	(Kim	et	al.,	2018).	We	found	that	CKD-504	reduced	tau	in	
AD	patient-iPSC-derived	brain	organoids.	In	addition,	CKD-504	sig-
nificantly reduced pathological tau and rescued synaptic pathologies 
and	 cognitive	 impairment	 in	 ADLPAPT	mice.	 Furthermore,	 HDAC6	
inhibition	by	CKD-504	regulated	the	interactions	of	tau	with	chap-
erones	and	E3	ligases	involved	in	the	chaperone	network,	by	increas-
ing	acetylation	of	tau,	chaperones,	and	E3	ligases	in	brain	organoids	
and in vivo, resulting in accelerated proteasomal degradation of tau. 
Therefore,	we	suggest	that,	by	modulating	acetylation	of	tau	and	a	
tau-degrading	chaperone	network,	CKD-504	is	a	prominent	poten-
tial	therapeutic	drug	candidate	in	AD.
2 | RESULTS
2.1 | CKD-504 selectively inhibits HDAC6 and is 
highly targeted to the brain
To	characterize	the	novel	HDAC6	 inhibitor,	CKD-504,	we	first	de-
termined	 its	 selectivity	 for	HDAC6	 by	measuring	 its	 half-maximal	
inhibitory	concentration	(IC50)	using	recombinant	human	HDAC	en-
zymes	and	HDAC	class-specific	substrates.	Heat	maps	of	IC50 values 
showed	 that	 CKD-504	 selectively	 inhibited	 HDAC6	 versus	 other	
HDAC	isoforms	compared	with	panobinostat,	a	pan-HDAC	inhibitor,	
which	showed	no	selectivity	among	HDAC	isoforms	(Figure	1a).	The	
IC50	value	of	CKD-504	against	HDAC6	was	72.2	nM.	The	specific-
ity	of	CKD-504	was	also	determined	using	HDAC6	knockout	 (KO)	
mouse	embryonic	fibroblasts	(MEFs)	as	well	as	wild-type	(WT)	MEFs	
(Jung	et	al.,	2018)	(Figure	1b).	CKD-504	increased	the	acetylation	of	
α-tubulin	in	a	dose-dependent	manner	in	WT	MEFs	with	no	changes	
in	acetyl-histone.	In	HDAC6	KO	MEFs,	the	basal	levels	of	acetyl-α-
tubulin	were	highly	 increased	as	previously	reported	 (Zhang	et	al.,	
2008)	 and	 CKD-504	 did	 not	 affect	 the	 acetylation	 levels	 of	 both	
α-tubulin	and	histone.	These	results	further	indicate	that	CKD-504	
selectively	 inhibits	 HDAC6.	 Next,	 we	 assessed	 pharmacokinetic	
parameters	of	CKD-504	by	measuring	its	concentrations	in	plasma	
and	 brain	 after	 a	 single	 intraperitoneal	 injection	 in	 ADLPAPT mice 
(Figure	1c,d,	Figure	S1a).	Plasma	and	brain	concentrations	of	CKD-
504	were	increased	in	a	dose-dependent	manner.	In	particular,	the	
concentration	of	CKD-504	was	higher	 in	the	brain	than	 in	plasma,	
implying	 that	 CKD-504	 is	 highly	 targeted	 to	 the	 brain	 and	 shows	
considerable	 penetration	 of	 the	 BBB.	 CKD-504	 was	 metabolized	
rapidly, with a t1/2	of	<0.5	hr.	These	data	indicate	that	CKD-504	is	a	
selective	HDAC6	inhibitor	that	is	applicable	to	CNS	diseases.
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2.2 | CKD-504 reduces pathological tau in AD 
patient-iPSC-derived brain organoids
Because	 AD	 patient-iPSC-derived	 brain	 organoids	 expressed	 dif-
ferentiated neuronal markers, not neural progenitor markers 
(data	 not	 shown)	 on	 days	 65–70	 after	 embryoid	 body	 formation,	
and	 showed	 similar	 pathological	 features	 of	 patients	 with	 AD	
(Figure	1e–i,	Figure	S1b,c),	they	are	appropriate	models	for	evalu-
ating	 therapeutic	effects	of	CKD-504.	 In	detail,	 though	α-tubulin	
was not altered, acetylated α-tubulin	was	decreased	and	HDAC6	
F I G U R E  1  CKD-504	selectively	inhibits	HDAC6	and	is	highly	targeted	to	the	brain,	and	reduces	pathological	tau	in	human	brain	
organoids.	(a)	Heat	maps	showing	in	vitro	IC50	values	(nM)	of	CKD-504	and	panobinostat	to	inhibit	HDAC	1–11	using	recombinant	human	
HDAC	enzymes	and	HDAC	class-specific	substrates.	(b)	Acetylation	levels	of	α-tubulin	and	histone	H4	by	treatment	of	CKD-504	on	WT	and	
HDAC6	KO	MEF	cells.	(c,	d)	Analysis	of	plasma	and	brain	concentrations	of	1	or	2.5	mg/kg	of	CKD-504	after	intraperitoneal	(i.p.)	injection	
to	ADLPAPT	mice	(n	=	3).	Mean	plasma	concentrations	versus	time	plots	(c)	and	plasma	and	brain	concentrations	of	CKD-504	at	the	indicated	
time	points	following	i.p.	injection	(d).	(e-g)	The	levels	of	acetylated	α-tubulin	and	HDAC6	in	healthy	control	and	AD	patient-derived	human	
brain	organoids.	Representative	immunoblot	images	(e)	and	quantification	(f,	g)	(n	=	5).	(h,	i)	Decreased	expression	level	of	acetylated	
α-tubulin	in	AD	patient-derived	human	brain	organoids	confirmed	by	immunohistochemistry.	Representative	images	(h)	and	quantification	
(i)	(n	=	3).	(j–m)	Decreased	amount	of	total	and	phosphorylated	tau	by	CKD-504	in	AD	patient-derived	human	brain	organoids.	Human	brain	
organoids were treated with 5 μM	of	CKD-504	for	4	hr.	Representative	images	(j)	and	quantification	(k)	(n	=	5).	Decreased	AT8-positive	tau	
by	immunohistochemistry.	MAP2	stained	for	neuronal	marker.	Representative	images	(l)	and	quantification	(m)	(n	=	4,	3).	Scale	bar:	100	μm. n 
means independent number of organoids. Data are expressed as mean ± SEM.	Student's	t tests. #p < .05, ##p	<	.01.	CKD,	CKD-504;	V,	vehicle
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was	increased	in	AD	brain	organoids	compared	with	healthy	con-
trol	 brain	 organoids,	 which	 were	 determined	 by	 Western	 blot-
ting	 and	 immunohistochemical	 analyses.	 In	 addition,	 pathological	
tau	 detected	 by	AT8	 and	AT180	 antibodies	was	 increased	 in	AD	
brain	organoids	compared	with	healthy	controls	(data	not	shown).	
Therefore,	we	evaluated	the	therapeutic	effects	of	CKD-504	in	AD	
brain	organoids	before	testing	in	AD	mouse	models.	The	amounts	
of	total	and	phosphorylated	tau	were	both	decreased	by	CKD-504	
in	AD	brain	organoids	 (Figure	1j–m).	These	data	 indicate	 the	po-
tential	 of	CKD-504	 to	 rescue	 tau	 pathologies	 in	AD.	 In	 addition,	
we observed that the amount of total tau was also decreased by 
CKD-504	in	healthy	control	brain	organoids	(Figure	S1d,e).	It	sug-
gests	that	CKD-504	has	a	great	potential	for	reducing	tau	in	both	
pathological and healthy conditions.
2.3 | CKD-504 rescues memory impairment and 
PSD-95 levels in ADLPAPT mice in a preventive 
experimental paradigm
As	an	 in	vivo	preclinical	 study,	we	 tested	 the	 therapeutic	efficacy	
of	CKD-504	 in	ADLPAPT	mice.	To	determine	 the	efficacy	of	CKD-
504 before and after memory impairment, which appears at about 
6	months	of	age	in	ADLPAPT	mice	(Kim	et	al.,	2018),	we	assigned	two	
cohorts	of	mice	to	preventive	or	therapeutic	models.	In	the	preven-
tive	model,	 dose-dependent	 efficacy	was	 tested	 by	 injecting	 two	
different	doses	of	CKD-504	(1	and	2.5	mg/kg)	for	4	months	begin-
ning	at	4.5	months	of	age.	Cognitive	functions	of	WT	and	ADLPAPT 
mice	were	assessed	using	Y-maze	and	contextual	fear	conditioning	
tests	 (Figure	2a,b).	 Even	 the	 low	dose	of	CKD-504	 (1	mg/kg)	 res-
cued	cognitive	dysfunction	in	ADLPAPT	mice.	To	determine	the	phar-
macodynamics	of	CKD-504	 in	the	brain,	acetylated	α-tubulin	 level	
was	analyzed	by	Western	blotting.	As	expected,	CKD-504	injected	
group showed increased levels of acetylated α-tubulin	levels,	which	
indicates	 that	 CKD-504	 has	 penetrated	 BBB	 and	 worked	 well	 in	
the	brain	(Figure	S1f,g).	In	addition,	normal	expression	levels	of	the	
postsynaptic	 protein,	 PSD-95,	 were	 retained	 in	 CKD-504-treated	
ADLPAPT	mice	(Figure	2c,d),	indicating	that	CKD-504	might	protect	
synaptic	proteins	from	damage.	These	data	show	that	CKD-504	has	
preventive	potential	in	ADLPAPT mice.
2.4 | CKD-504 reduces pathological tau in ADLPAPT 
mice in a preventive experimental paradigm
Next,	we	 sought	 to	 determine	whether	CKD-504	 affected	Aβ or 
tau pathologies, which are possible mechanisms by which it might 
prevent	 memory	 impairment.	 To	 measure	 Aβ plaques, we per-
formed	 immunohistochemistry	 using	 the	 antibody,	 4G8	 (Figure	
S1h–j).	Aβ	plaques	were	not	significantly	reduced	in	ADLPAPT mice 
by	 CKD-504,	 although	 it	 caused	 a	 tendency	 toward	 a	 decrease	
in	Aβ plaques in the dentate gyrus. Neuroinflammation, assessed 
using	an	anti-Iba-1	antibody,	was	also	unchanged	by	CKD-504	 in	
ADLPAPT	mice	 (Figure	S1k–m).	However,	we	 found	 that	CKD-504	
did	reduce	tau	pathology	in	ADLPAPT	mice	(Figure	2e-j,	Figure	S2),	
a	 finding	 consistent	with	 results	 obtained	with	AD	 patient-iPSC-
derived	 brain	 organoids.	 CKD-504	 reduced	 the	 amount	 of	 total	
tau	 and	 phosphorylated	 tau	 (pT181,	 pS199,	 pS262,	 pT231,	 and	
pS396)	in	the	sarkosyl-soluble	fraction	at	both	doses	(Figure	2e–g,	
Figure	 S2a–f).	 The	 amounts	 of	 total	 tau	 and	 phosphorylated	 tau	
(AT8,	AT180,	pS356,	and	pS262)	in	the	sarkosyl-insoluble	fraction,	
which	contains	higher-order	filamentous	aggregates	of	tau	(Ren	&	
Sahara,	2013),	were	also	reduced	by	CKD-504	(Figure	2h,i,	Figure	
S2g–k).	 In	 addition,	 immunohistochemical	 analyses	 using	 Tau-13,	
AT8,	and	AT180	antibodies	consistently	showed	that	CKD-504	de-
creased	the	amounts	of	total	and	phosphorylated	tau	 in	ADLPAPT 
mice	 (Figure	 2j,	 Figure	 S2l–q).	 Moreover,	 we	 confirmed	 that	 the	
decreased tau did not result from transcriptional regulation of 
tau	 (Figure	 S2r).	 These	 results	 demonstrate	 that	 a	 1	mg/kg	dose	
of	CKD-504	was	sufficient	to	rescue	tau	pathologies,	which	might	
contribute to the rescue of memory impairment, but did not rescue 
Aβ pathology or neuroinflammation.
2.5 | CKD-504 rescues memory impairment and 
synaptic and tau pathologies in ADLPAPT mice in 
a therapeutic experimental paradigm
We	 investigated	 whether	 CKD-504	 exerts	 therapeutic	 efficacy	
after	 the	 appearance	 of	 memory	 impairment.	 Because	 ADLPAPT 
mice	 show	 cognitive	 impairment	 from	 6-month-old	 (Kim	 et	 al.,	
2018),	 we	 employed	 a	 therapeutic	 paradigm	 with	 6.5-month-
old	 ADLPAPT	 mice.	 Those	 mice	 were	 injected	 with	 CKD-504	 for	
2	months.	In	this	experimental	paradigm,	CKD-504	rescued	mem-
ory	impairment	in	ADLPAPT	mice,	as	assessed	by	Y-maze	and	con-
textual	fear	conditioning	tests	(Figure	3a,b).	PSD95	level	followed	
the same trends as memory recovery, showing tendency of restora-
tion	measured	by	Western	blotting	(Figure	S3a,b).	Dendritic	spine	
density,	 measured	 by	 Golgi–Cox	 staining,	 was	 also	 significantly	
restored	 (Figure	3c,d).	Although	Aβ pathologies and neuroinflam-
mation,	analyzed	using	ELISA	and	immunohistochemistry,	were	not	
changed	by	CKD-504,	tau	pathologies	were	reduced	(Figure	S3c–h,	
Figure	 3e–n).	 Specifically,	 Tris-buffered	 saline	 (TBS)-fractionated	
tau,	 which	 includes	 both	 sarkosyl-soluble	 and	 sarkosyl-insoluble	
tau,	 was	 reduced	 by	 CKD-504	 (Figure	 3e–g).	 CKD-504	 also	 re-
duced	 the	 amounts	 of	 total	 and	 phosphorylated	 tau	 in	 sarkosyl-
soluble	and	sarkosyl-insoluble	fractions	(Figure	3h–l,	Figure	S3i–p).	
Moreover,	the	intensity	of	AT180	staining	in	immunohistochemical	
analyses	 was	 consistently	 decreased	 by	 CKD-504	 (Figure	 3m,n).	
These	data	show	that	CKD-504	rescues	memory	impairment,	syn-
aptic pathology, and tau pathologies, not only in the preventive 
model	but	also	in	the	therapeutic	model.	Because	CKD-504	exerts	
therapeutic efficacy when administered at any stage of the disease, 
it	might	be	a	potential	therapeutic	drug	for	AD.
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2.6 | CKD-504 potentiates proteasomal 
degradation of tau by changing their protein 
interactome to a chaperone network
Based	on	our	major	finding	that	 inhibition	of	HDAC6	by	CKD-504	
reduced pathological tau, we next sought to investigate the underly-
ing	mechanisms.	First,	we	examined	whether	HDAC6	regulated	the	
turnover	of	tau	in	vitro.	To	measure	the	turnover	rate	of	tau,	we	co-
transfected	HT22	cells	with	human	mutant	tau	(P301L)	and	HDAC6	
plasmids	and	then	treated	these	cells	with	cycloheximide	(CHX),	to	
inhibit	de	novo	protein	synthesis	 (Figure	S4a,b).	HT22	cells,	 trans-
fected	 with	 human	 mutant	 tau	 (P301L)	 alone,	 were	 treated	 with	
CKD-504	and	CHX	(Figure	S4c,d).	The	tau	degradation	rate	was	de-
creased	in	cells	overexpressing	HDAC6	compared	with	mock-trans-
fected	cells	and	was	increased	by	CKD-504	compared	with	vehicle.	
These	results	show	that	HDAC6	negatively	regulates	the	degrada-
tion rate of tau. Next, because tau is degraded by both the UPS and 
ALS	(Lee	et	al.,	2013),	we	investigated	which	of	these	two	systems	
is	involved	in	the	CKD-504-induced	degradation	of	tau	in	AD	brain	
organoids,	P301L-tau	transfected	HT22	cells,	and	ADLPAPT	mice.	We	
observed	that	CKD-504	reduced	tau	in	AD	brain	organoids	treated	
with vehicle and lysosomal inhibitor, but failed to degrade tau in the 
presence	of	proteasomal	 inhibitor,	MG132,	showing	effects	of	 tau	
degradation	with	CKD-504	are	mediated	by	proteasomal	degrada-
tion	pathway	 (Figure	4a,b).	To	confirm	this	result	 in	vitro,	we	used	
several	different	inhibitors	in	HT22	cells.	Consistent	with	the	results	
in	human	brain	organoids,	CKD-504	accumulated	tau	in	HT22	cells	
in	the	presence	of	MG132,	but	not	in	the	presence	of	lysosome	or	
autophagy	inhibitors	(Figure	S4e,f).	In	this	overexpression	system	of	
HT22	cells,	because	accelerated	degradation	rate	by	CKD-504	might	
F I G U R E  2  CKD-504	recovered	
cognitive impairment and synaptic 
pathology, and reduced tau in the 
preventive	model	of	ADLPAPT	mice.	(a,	
b)	Cognitive	impairment	was	rescued	
by	CKD-504	injection	for	4	months	
in	4.5-month-old	ADLPAPT mice. 
Quantification	of	Y-maze	test	(a)	and	CFC	
test	(b)	(n	=	7–12).	(c,	d)	Reduced	PSD-
95	levels	were	rescued	by	CKD-504	in	
the cortex. Representative immunoblot 
images	(c)	and	quantification	(d)	(n	=	7–10).	
(e–i)	Sarkosyl-soluble	and	sarkosyl-
insoluble tau proteins were decreased by 
CKD-504.	Total	and	phosphorylated	tau	
proteins were detected by the indicated 
primary antibodies. Representative 
immunoblot images and quantification 
of	sarkosyl-soluble	fraction	(e–g)	and	
sarkosyl-insoluble	fraction	(h,	i)	of	
hippocampal	lysates	from	ADLPAPT 
mice.	Quantification	of	phosphorylated	
tau	is	shown	in	Figure	S2.	(j)	Total	and	
phosphorylated tau proteins were 
reduced in the hippocampus as confirmed 
by immunohistochemistry. Representative 
images	(j)	shown	here	and	quantifications	
are in Figure S2. Scale bar: 100 μm. Data 
are presented as means ± SEM.	Two-way	
ANOVA	in	(a,	b,	d,	g)	and	one-way	ANOVA	
in	(f,i)	followed	by	Bonferroni	post	hoc	
test. *p < .05, **p < .01, ***p < .001. 
Student's	t tests. #p	<	.05.	CKD,	CKD-504
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be insufficient for overcoming expression rate of overexpressed tau, 
CKD-504	could	not	 reduce	 tau	 level	 in	 the	vehicle.	Therefore,	 ac-
cumulated	 tau	 by	 CKD-504	 by	 MG132	 indicates	 that	 CKD-504	
promotes proteasomal degradation of tau. Moreover, ubiquitinated 
tau	was	increased	by	CKD-504	in	the	presence	of	the	proteasome	
inhibitor	in	HT22	cells	(Figure	S4g).	In	the	same	vein,	autophagy-lys-
osomal	flux	was	not	rescued	by	CKD-504	in	HT22	cells	and	ADLPAPT 
mice,	as	evidenced	by	 the	absence	of	changes	 in	ALS-related	pro-
teins	(Figure	S5a–h).	These	data	suggest	that	CKD-504	potentiates	
proteasomal degradation of tau.
Ubiquitination and proteasomal degradation of proteins are reg-
ulated by a chaperone network that includes heat shock proteins 
and	 E3	 ligases	 (Vilchez,	 Saez,	 &	Dillin,	 2014).	 Because	 CKD-504	
did	 not	 affect	 proteasome	 activity	 (Figure	 S5i),	 we	 hypothesized	
that	 CKD-504	 regulates	 interactions	 between	 tau	 and	 chaper-
ones	 or	 co-chaperones.	 To	 test	 this	 hypothesis,	we	 performed	 a	
tau-interactome	 analysis	 by	 mass	 spectrometry	 using	 saline-	 or	
CKD-504-injected	ADLPAPT	mouse	brain	 samples	 co-immunopre-
cipitated	 (co-IPed)	 with	 Tau-13	 antibody.	 We	 identified	 265	 dif-
ferentially	 interacting	 proteins	 in	 the	 CKD-504	 group	 compared	
with	the	saline	group	(t test FDR <0.05, absolute log2 fold change 
≥0.58)	(Tables	S1	and	S2).	Several	unexpected	E3	ligases	(Mycbp2,	
UBE2O,	RNF14,	Huwe1)	which	have	not	been	reported	to	targeting	
tau were shown to exhibit increased interactions with tau following 
treatment	with	CKD-504.	An	enrichment	analysis	of	gene	ontology	
biological	processes	(GOBPs)	revealed	that	among	the	tau	interac-
tors	 that	 showed	 increased	 interactions	 in	 response	 to	CKD-504	
included	 a	 significant	 number	 of	microtubule-associated	 proteins	
(Figure	S6),	supporting	the	validity	of	our	proteomic	analysis.	This	
analysis further showed that heat shock proteins were signifi-
cantly enriched among tau interactors that showed increased in-
teractions	in	response	to	CKD-504	(Figure	4c,d).	These	heat	shock	
F I G U R E  3  CKD-504	recovered	
memory impairment and dendritic spine 
density, and reduced tau in therapeutic 
model	of	ADLPAPT	mice.	(a,	b)	Cognitive	
impairment	was	rescued	by	CKD-504	
injection	for	2	months	in	6.5-month-old	
ADLPAPT	mice.	Quantification	of	Y-maze	
test	(a)	and	CFC	test	(b)	(n	=	16–22).	(c,	
d)	CKD-504	rescued	dendritic	spine	
density in the cortex. Representative 
images	(c)	and	quantification	(d)	of	cortical	
spines	(n	=	16–29	dendrites	from	3	mice	
per	group).	(e-g)	Representative	images	
(e)	and	quantification	(f,	g)	of	dot	blot	
showing	that	CKD-504	reduced	total	
tau	(n	=	5–6).	(h–l)	Sarkosyl-soluble	and	
sarkosyl-insoluble	tau	proteins	were	
decreased	by	CKD-504.	Representative	
immunoblot images and quantification 
of	tau	from	sarkosyl-soluble	fraction	
(h-j)	and	sarkosyl-insoluble	fraction	(k,	
l)	of	hippocampal	lysates	from	ADLPAPT 
mice	(n	=	5).	Representative	images	
and quantifications of phosphorylated 
tau	are	in	Figure	S3.	(m,	n)	AT180	
immunoreactivity was reduced in the 
hippocampus. Representative images 
(m)	and	quantification	(n)	(n	=	10,	5).	
Scale bar: 100 μm. Data are presented as 
means ± SEM.	Two-way	ANOVA	followed	
by Bonferroni post hoc test. *p < .05, 
**p < .01, ***p	<	.001.	Student's	t tests. 
#p	<	.05.	CKD,	CKD-504;	Sal,	Saline
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proteins	included	members	of	the	Hsp40	family	(Dnaja1,	Dnaja2),	
Hsp70	family	(Hspa1a/Hsp70,	Hspa4l,	Hspa8/Hsc70),	Hsp60	fam-
ily	 (Hspd1),	 and	Hsp110	 family	 (Hsph1).	 These	 data	 indicate	 that	
CKD-504	 increases	 interactions	between	tau	and	chaperone	net-
work proteins, an effect that could be responsible for the observed 
proteasomal degradation of tau.
F I G U R E  4  CKD-504	potentiated	proteasomal	degradation	of	tau	by	changing	tau	protein	interactome	to	chaperone	network	proteins	
such	as	heat	shock	proteins	and	E3	ligases.	(a,	b)	Degradation	of	tau	by	CKD-504	is	mediated	by	proteasomal	degradation	in	AD	patient-
derived brain organoids. Brain organoids were treated with 20 μM	of	MG132	or	5	nM	of	bafilomycin	for	4	hr.	Representative	images	(a)	
and	quantification	(b)	(n	=	3).	(c,	d)	The	heat	map	represents	log2 fold changes of intensities reflecting interaction strength, which were 
measured	by	mass	spectrometric	analysis	in	CKD-504-treated	samples	relative	to	saline	controls.	The	color	bar	shows	a	gradient	of	log2 fold 
changes.	(e–g)	CKD-504	increased	acetylation	and	interactions	between	tau	and	chaperones	in	ADLPAPT mice. Human tau and acetylated 
proteins	were	immunoprecipitated	by	Tau-13	antibodies	and	anti-acetyl	lysine	antibody-conjugated	beads,	respectively.	Representative	
images	(e)	and	quantification	(f,	g)	(n	=	3–5).	(h,	i)	CKD-504	increased	the	interaction	between	tau	and	UBE2O	in	ADLPAPT mice. Human 
tau	was	immunoprecipitated	by	Tau-13	antibodies	(n	=	4).	(j-l)	UBE2O	ubiquitinated	and	reduced	tau.	Tau	overexpressed	HT22	cells	were	
transfected	with	mock	or	UBE2O	(MG132:	5	μM,	24	hr).	Representative	images	(j)	and	quantification	(k,	l)	(n	=	5,	independent	experiments).	
Data are presented as means ± SEM.	One-way	ANOVA	followed	by	Bonferroni	post	hoc	test.	**p	<	.01.	Student's	t tests. #p < .05, ##p < .01, 
###p	<	.001.	Ac-K,	acetylated	lysine;	Baf,	bafilomycin;	CKD,	CKD-504;	S,	saline;	Ub,	ubiquitin
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Next, we validated the differentially increased interactions 
between	 tau	 and	 chaperones	 and	 co-chaperones	 induced	 by	
CKD-504.	It	has	been	reported	that	Hsc70,	Hsp70,	and	E3	ligases	
interact with tau and promote proteasomal degradation of tau 
(Shimura,	 Schwartz,	 Gygi,	 &	 Kosik,	 2004;	Wang,	 Tan,	 Lu,	 Yu,	 &	
Tan,	2014).	Thus,	to	determine	whether	CKD-504	alters	 interac-
tions among tau, Hsc70, and Hsp70, we immunoprecipitated brain 
lysates	 with	 a	 Tau-13	 antibody	 and	 probed	 immunoprecipitates	
with	antibodies	against	Hsc70	and	Hsp70.	As	expected,	 interac-
tions	 among	Hsc70,	Hsp70,	 and	 tau	were	 increased	 in	ADLPAPT 
mice	injected	with	CKD-504	compared	with	saline-injected	mice	
(Figure	4e–g).	Moreover,	 interaction	with	tau	and	UBE2O,	an	E3	
ligase newly identified targeting tau in this study, was increased 
in	ADLPAPT	mice	injected	with	CKD-504	compared	with	saline-in-
jected	mice	(Figure	4h,i).	Therefore,	these	data	demonstrate	that	
CKD-504	 regulates	 interactions	 between	 tau	 and	 chaperone	
network proteins.	We	further	determined	the	activity	of	UBE2O	
as	 an	 E3	 ligase	 of	 tau	 by	 overexpressing	UBE2O	 in	HT22	 cells.	
UBE2O	 overexpressed	 HT22	 cells	 showed	 a	 decreased	 level	 of	
tau	and	 increased	ubiquitination	of	 tau	 (Figure	4j–l).	From	these	
results,	UBE2O	might	be	a	novel	E3	ligase	targeting	tau.	Because	
HDAC6	 regulates	 acetylation	 of	 proteins,	 we	 considered	 the	
possibility	that	CKD-504	increased	acetylation	of	tau	and	tau	in-
teractors.	To	detect	 acetylation	 levels	of	 these	proteins,	we	 im-
munoprecipitated	 lysates	 with	 anti-acetyl	 lysine	 affinity	 beads	
and	 then	probed	beads	with	 the	 indicated	antibodies.	CKD-504	
increased	acetylation	of	Hsc70,	Hsp70,	and	tau	in	ADLPAPT mice 
(Figure	 4e–g).	 Consistent	 with	 in	 vivo	 data,	 interactions	 among	
tau	 and	 chaperones	 (Hsp105,	Hsp70,	Hsc70,	Dnaja1),	 E3	 ligases	
(RNF14,	 UBE2O),	 and	 also	 acetylation	 of	 chaperones	 and	 E3	 li-
gases	were	 increased	by	CKD-504	 in	brain	organoids	 (Figure	5).	
These	results	suggest	that	CKD-504	increases	interactions	among	
chaperone network proteins and tau by increasing acetylation 
of tau and several chaperone network proteins, which leads to 
proteasomal	degradation	of	 tau	 (Figures	2,	3,	and	4a).	Thus,	our	
findings	demonstrate	that	CKD-504	facilitates	proteasomal	deg-
radation of tau by regulating the acetylation level of tau and chap-
erone network proteins.
2.7 | Acetylation at K274, K290, K321, and K353 of 
tau regulates tau turnover rate
As	previously	reported,	CKD-504	regulates	tau	acetylation	by	inhib-
iting	HDAC6	(Carlomagno	et	al.,	2017;	Cook	et	al.,	2014;	Ding	et	al.,	
2008).	However,	the	acetylation	sites	that	contribute	to	proteaso-
mal	degradation	of	tau	were	unclear.	It	has	been	reported	that	tau	
acetylation at K274, K290, K321, and K353—the acetylation sites 
regulated	 by	 HDAC6—decreases	 heparin-induced	 aggregation	 of	
tau	(Carlomagno	et	al.,	2017).	In	addition,	275VQII278 and 306VQIV309 
motifs	in	the	microtubule-binding	domain	of	tau	are	known	to	me-
diate	tau	association	with	Hsc70	and	Hsp70	(Sarkar,	Kuret,	&	Lee,	
2008).	K274,	 one	of	 the	 four	 aforementioned	 acetylation	 sites,	 is	
located immediately before the 275VQII278	motif.	Therefore,	we	hy-
pothesized	that	acetylation	of	tau	at	K274,	K290,	K321,	and	K353	
regulates interactions among tau and chaperone network proteins 
and	 degradation	 of	 tau.	 To	 test	 this	 hypothesis,	 we	 constructed	
acetyl-mimic	or	acetyl-silencing	mutants	by	substituting	two	lysine	
sites	 (K274,	K321),	which	 are	 the	most	 effective	 anti-aggregation	
sites,	and	all	four	lysine	sites	(K274,	K290,	K321,	and	K353)	with	glu-
tamine	(2KQ,	4KQ)	or	arginine	(2KR,	4KR),	respectively,	in	both	nor-
mal	tau	indicated	by	WT	tau	and	pathological	tau	such	as	P301L-tau.	
Subsequently,	we	tested	the	interactions	among	WT	tau	or	mutant	
tau	 and	 the	 representative	 chaperone	 network	 proteins	 in	 HT22	
cells.	 Interaction	 between	 Hsp70	 and	 tau	 was	 increased	 in	 2KQ	
mutants,	but	not	in	2KR	mutants	(Figure	S7a–c).	However,	turnover	
rates	of	tau	were	not	altered	in	both	2KQ	and	2KR	mutants	(Figure	
S7d–g).	As	2KQ	mutants	showed	increased	interaction	with	Hsp70	
but did not change the turnover rate of tau, we subsequently evalu-
ated	effects	of	4KQ	and	4KR	mutants,	which	are	additionally	modu-
lated	acetylation	sites.	4KQ	mutants	showed	increased	interactions	
with Hsc70 and Hsp70, whereas interactions of 4KR mutants with 
those	chaperones	were	unaltered	compared	with	WT,	which	is	simi-
lar	to	2KQ/2KR	mutants	(Figure	6a–e).	However,	turnover	rates	of	
4KQ	mutants	in	HT22	cells	were	increased	compared	with	WT	and	
4KR	mutant	(Figure	6f,j,	Figure	S7h).	These	results	suggest	that	all	
four acetylation sites that we have tested are important for promot-
ing degradation of tau.
To	 determine	 whether	 acetylation	 on	 K274,	 K290,	 K321,	 and	
K353	of	tau	 is	responsible	for	regulating	tau	degradation	by	CKD-
504,	we	observed	the	effect	of	CKD-504	on	4KQ	or	4KR	mutants	
(Figure	6g,h,j,k,	Figure	S7a).	CKD-504	did	not	accelerate	the	degra-
dation	rate	of	tau	in	the	4KQ	mutant,	which	means	that	acetylation	
on the four residues of tau is responsible for regulating tau degra-
dation.	 However,	 CKD-504	 increased	 the	 degradation	 rate	 of	 tau	
in	4KR	mutant.	It	might	be	because	CKD-504	increases	acetylation	
of	chaperones,	E3	ligases,	and	other	HDAC6-regulated	sites	on	tau.	
These	results	suggest	that	acetylation	on	the	four	lysine	residues	of	
tau is sufficient for promoting tau degradation.
Collectively, our findings demonstrate that acetylation of tau on 
K274, K290, K321, and K353 sufficiently regulates the turnover rate 
of tau by recruiting Hsc70 and Hsp70 to tau.
3  | DISCUSSION
In	 the	 present	 study,	we	 demonstrated	 the	 therapeutic	 efficacy	
of	 CKD-504,	 a	 novel	 and	 selective	HDAC6	 inhibitor	 that	 shows	
high	penetration	 in	 the	brain.	CKD-504	rescued	memory	 impair-
ment	and	synaptic	pathology	in	ADLPAPT mice, which exhibit both 
Aβ	 and	 tau	pathologies	 similar	 to	patients	with	AD,	primarily	 by	
reducing	pathological	 tau.	 In	 addition,	CKD-504	 reduced	patho-
logical	tau	in	AD	patient-iPSC-derived	brain	organoids,	suggesting	
that	CKD-504	might	efficiently	 regulate	 tau	 in	 the	human	brain.	
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CKD-504	also	regulated	acetylation	of	tau	and	the	chaperone	pro-
teins such as Hsc70 and Hsp70, enhancing the interactions among 
these	proteins	 as	well	 as	 the	 recruitment	of	 the	novel	 tau	E3	 li-
gases	(UBE2O	and	RNF14),	followed	by	ubiquitination	and	protea-
somal	degradation	of	tau	(Figure	6l).	Moreover,	we	revealed	that	
acetylation on K274, K290, K321, and K353 of tau is involved in 
proteasomal	degradation	of	tau	by	CKD-504.	Taken	together,	our	
findings	elucidate	the	mechanism	by	which	the	HDAC6	inhibitor,	
CKD-504,	causes	tau	degradation,	thereby	establishing	its	thera-
peutic potential.
A	 recent	 study	 reported	 that	 another	 HDAC6	 inhibitor,	
MPT0G211,	 increased	acetylation	of	Hsp90	and	ubiquitination	of	
phosphorylated	 tau	 (Fan,	 Huang,	 Liou,	 &	 Yang,	 2018).	 However,	
the	 precise	 mechanism	 of	 tau	 ubiquitination	 was	 unclear.	 In	 the	
current	study,	we	demonstrated	that	CKD-504	recruited	the	E3	li-
gases to tau by increasing acetylation of tau and several chaperone 
network proteins such as Hsp105, Hsc70, Hsp70, Dnaja1, RNF14, 
and	 UBE2O,	 thereby	 enhancing	 complex	 formation.	 In	 addition,	
we	 identified	 UBE2O	 and	 RNF14	 as	 novel	 E3	 ligases	 of	 tau	 and	
showed	that	CKD-504	increased	the	interaction	of	these	proteins	
with	 tau	 in	mouse	brain	 and	patient-derived	human	brain	 organ-
oids.	The	specific	role	of	each	of	these	proteins	will	be	examined	in	
future studies. However, based on previous reports about Hsp40 
and	Hsp110	family	(details	in	extended	discussions),	CKD-504	may	
decrease tau aggregates by inhibiting hyperphosphorylation and 
aggregation or by promoting disaggregation; it may also promote 
tau clearance by regulating the aforementioned chaperones and 
co-chaperones.	Therefore,	we	demonstrated	for	the	first	time	that	
an	HDAC6	inhibitor	could	orchestrate	a	chaperone	network	rather	
than merely a single component.
We	also	 determined	 that	 acetylation	 of	 tau	 on	K274,	K290,	
K321, and K353 plays an important role in the formation of 
complexes with chaperones and degradation of tau. Because 
CKD-504	 has	 no	 additive	 effects	 on	 the	 degradation	 of	 tau	 in	
4KQ	mutant,	 the	 acetylation	 on	 the	 four	 lysine	 residues	 of	 tau	
is	 sufficient	 for	 promoting	 the	degradation	of	 tau	by	CKD-504.	
In	addition,	the	results	of	2KQ	mutants,	in	which	the	interaction	
between Hsp70 and tau was increased, whereas turnover rates 
of tau were not altered, also show the four acetylation sites are 
important	 for	 promoting	 tau	 degradation.	 Since	 4KQ	 mutants	
regulate both interaction between chaperones and tau and turn-
over rates of tau, the results of double mutants suggest that the 
role of acetylation on K274 and K321 of tau is only regulating the 
interaction	with	chaperones	such	as	Hsp70.	 It	 seems	 that	other	
acetylation sites—K290 and K353—might be responsible for an 
additional mechanism for tau degradation such as binding with 
E3	 ligases.	 Indeed,	 275VQII278 and 306VQIV309 motifs of tau are 
known	to	mediate	tau	association	with	Hsc70	and	Hsp70	(Sarkar	
et	al.,	2008),	which	 implies	 that	K274	and	K321	are	responsible	
for	 interacting	 with	 Hsp70.	 In	 addition,	 UBE2O,	 one	 of	 the	 E3	
ligases	that	is	validated	in	this	study,	was	known	to	bind	with	VLI	
patch	(Mashtalir	et	al.,	2014).	K290	and	K353	are	located	within	
the	similar	sequence	with	VLI	patch	motif	on	microtubule-binding	
regions	(244–367	a.a.)	of	tau.	Therefore,	acetylation	on	K290	and	
K353	of	tau	might	be	critical	for	binding	E3	ligases.	Collectively,	
all four sites that we have tested are important acetylation sites 
for	 tau	 interaction	with	 chaperones	 and	 E3	 ligases,	 which	 pro-
motes the degradation of tau.
CKD-504	rescued	memory	impairment	in	ADLPAPT mice in both 
preventive and therapeutic experimental paradigms, in which mice 
were	 injected	with	CKD-504	before	or	after	memory	 impairment	
appeared,	respectively.	This	indicates	that	CKD-504	not	only	pro-
tects against the development of cognitive dysfunction, but it also 
rescues	 impaired	 cognitive	 function	 in	 ADLPAPT	mice.	 Given	 that	
F I G U R E  5  CKD-504	increased	interaction	and	acetylation	of	chaperone	network	proteins	in	AD	patient-iPSC-derived	brain	organoids.	
(a-d)	CKD-504	increased	acetylation	and	interactions	between	tau	and	chaperone	network	proteins	in	AD	brain	organoids.	Human	tau	and	
acetylated	proteins	were	immunoprecipitated	by	Tau-13	and	anti-acetyl	lysine	antibody-conjugated	beads.	Representative	images	(a,	b)	and	
quantification	(c,	d).	n means independent number of organoids. Data are presented as means ± SEM.	Student's	t tests. #p < .05, ##p < .01, 
###p	<	.001.	Ac-K,	acetylated	lysine;	CKD,	CKD-504;	Veh,	vehicle
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many	AD	clinical	trials,	including	those	involving	AD	dementia	pa-
tients,	have	failed	and	recent	AD	clinical	 trials	 tend	to	recruit	pa-
tients	 with	 preclinical	 and	 prodromal	 AD	 (Anderson	 et	 al.,	 2017;	
Cummings,	 Lee,	Mortsdorf,	 Ritter,	 &	 Zhong,	 2017),	 the	 ability	 of	
CKD-504	to	rescue	memory	impairment	even	in	a	therapeutic	ex-
perimental paradigm suggests that this agent has strong potential 
for	treating	AD.	In	addition,	other	therapeutic	effects	of	CKD-504	
and	 a	 prolonged	 effect	 after	 washout	 of	 CKD-504	 support	 the	
strong	therapeutic	potential	of	CKD-504	(Figure	S8,	extended	dis-
cussion).	Higher-order	aggregates	of	tau	are	known	to	be	degraded	
by	the	ALS,	whereas	buffer-soluble	tau	is	cleared	by	the	UPS	(Lee	
et	al.,	2013).	Higher-order	aggregates	of	tau,	which	are	present	in	
a	 sarkosyl-insoluble	 fraction	 (Ren	&	 Sahara,	 2013)	 from	ADLPAPT 
mice,	were	 reduced	 by	CKD-504,	 despite	 the	 fact	 that	CKD-504	
does	not	affect	the	ALS.	It	has	been	reported	that	increased	acetyl-
ation	 of	 tau	 at	 HDAC6-regulating	 sites,	 such	 as	 KXGS	 motifs	
and	 K274,	 inhibits	 aggregation	 of	 tau	 (Carlomagno	 et	 al.,	 2017).	
Therefore,	a	reduction	in	sarkosyl-insoluble	tau	by	CKD-504	might	
have	resulted	from	blocking	tau	aggregation	by	HDAC6	inhibition,	
followed by proteasomal degradation of soluble aggregates of 
tau.	The	HDAC6-regulating	sites,	K274	and	K280,	are	well-known	
pathological	acetylation	sites	of	tau	(Carlomagno	et	al.,	2017;	Irwin	
et	al.,	2012;	Tracy	et	al.,	2016).	However,	the	apparent	net	effect	of	
CKD-504	on	degrading	tau	may	indicate	that	a	number	of	acetyla-
tion	sites	are	regulated	by	HDAC6	function	together.	Additionally,	
K174 and K281, two other reported pathological acetylation sites 
of	tau,	are	not	regulated	by	HDAC6	(Carlomagno	et	al.,	2017;	Min	et	
al.,	2015;	Sohn	et	al.,	2016).
F I G U R E  6  Acetylation	on	K274,	
K290, K321, and K353 of tau regulates 
interaction with chaperones and 
degradation	rate	of	tau.	(a–k)	Acetyl-mimic	
and	acetyl-silencing	mutations	on	K274,	
K290,	K321,	and	K353	of	P301L	and	WT	
tau regulated interactions with tau and 
chaperones	in	HT22	cells.	Representative	
immunoblot	images	(a)	and	quantification	
of	mutations	in	P301L	tau	(b,	c)	and	in	WT	
tau	(d,	e)	(n	=	3,	independent	experiments).	
Data are presented as means ± SEM.	One-
way	ANOVA	followed	by	Bonferroni	post	
hoc test. *p < .05, **p < .01, ***p < .001. 
(f–k)	Quantitative	graphs	of	altered	
degradation	rate	of	tau	by	acetyl-
mimic	and	acetyl-silencing	mutations	
in	tau	and	CKD-504.	Representative	
immunoblot images in Figure S7h. Data 
are presented as means ± SEM.	Analysis	
of	covariance	(ANCOVA).	*p < .05, 
**p	<	.01.	(l)	Schematic	diagram	of	the	
mechanism	of	tau	degradation	by	CKD-
504.	In	AD,	as	overall	level	of	acetylation	
is	down-regulated,	interactions	of	tau	
with	chaperones	and	E3	ligases	may	be	
insufficient to degrade pathologic tau. 
Consequently, tau is hardly degraded by 
UPS	and	becomes	aggregated.	CKD-504,	
an	HDAC6	inhibitor,	increases	acetylation	
levels of tau and several chaperone 
network	proteins	and	E3	ligases	and	
increases interactions with tau, resulting 
in promoting proteasomal degradation 
of	tau.	Finally,	reduced	tau	by	CKD-504	
leads to rescue of cognitive impairment in 
AD	model	mice
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In	 summary,	 we	 demonstrated	 that	 acetylation	 regulated	 by	
CKD-504,	 a	 highly	 selective	 HDAC6	 inhibitor	 with	 efficient	 BBB	
penetration, potentiated proteasomal degradation of tau by orches-
trating	 a	 tau-regulated	 chaperone	 network.	 Specifically,	 CKD-504	
increased	acetylation	of	several	chaperones	and	E3	 ligases	as	well	
as	 tau	 itself,	 resulting	 in	 recruitment	of	 the	novel	 tau	targeting	E3	
ligases	such	as	UBE2O	and	RNF14	to	tau,	which	lead	to	the	rescue	of	
synaptic	pathology	and	memory	impairment	in	ADLPAPT	mice.	These	
results allowed us to elucidate the precise mechanism of tau degra-
dation	by	HDAC6	inhibition,	 in	particular	showing	that	acetylation	
of tau at K274, K290, K321, and K353 plays an important role in 
tau	degradation.	In	addition,	CKD-504	showed	therapeutic	effects	
in	both	preventive	and	therapeutic	experimental	paradigms.	Taken	
together,	our	results	suggest	that	HDAC6	inhibitor	could	be	a	potent	
therapeutic	drug	candidate	in	AD	that	acts	by	modulating	tau	as	well	
as	a	tau-degrading	chaperone	network.
4  | E XPERIMENTAL PROCEDURES
4.1 | Animals and intraperitoneal injections
5XFAD	 mice	 (Tg6799;	 Jackson	 Laboratory,	 Stock#006554)	 and	
JNPL3	mice	 (TauP301L-JNPL3;	 Taconic,	 Stock#2508	 homozygote)	
are	 crossed	 to	 produce	 ADLPAPT	 mice.	 As	 background	 of	 JNPL3	
mice	is	differ	from	5XFAD	mice,	JNPL3	mice	were	backcrossed	with	
B6SJL	 (C57BL/6	X	 SJL)	mice	 before	 crossing	with	 5xFAD.	 Female	
WT	and	ADLPAPT	mice	were	used	for	brain	tissue	analysis	after	CKD-
504	 (Chong	 Kun	 Dang,	 South	 Korea)	 injection.	We	 designed	 two	
models	to	determine	the	efficacy	of	CKD-504	before	or	after	mem-
ory	impairment	which	appeared	around	6-month-old	ADLPAPT mice 
(Kim	et	al.,	2018).	For	the	preventive	model,	CKD-504	(1	or	2.5	mg/
kg)	 or	 saline	 were	 administered	 intraperitoneally	 to	 4.5-month-
old mice, twice a day, for four months. For the therapeutic model, 
2.5	mg/kg	of	CKD-504	or	saline	was	administered	intraperitoneally	
to	6.5-month-old	mice,	twice	a	day,	for	two	months.	Animals	were	
treated	and	maintained	in	accordance	with	the	Animal	Care	and	Use	
Guidelines	of	Seoul	National	University,	Seoul,	Korea.
4.2 | Behavioral tests
For	Y-maze	test,	a	mouse	was	introduced	to	the	middle	of	maze	and	
allowed	to	freely	explore	the	maze	for	8	min.	Spontaneous	alterna-
tion	was	measured	to	analyze	spatial	memory	function.	To	calculate	
percentage of spontaneous alternation, the number of sequential 
entries	to	different	Y-maze	arms	was	divided	by	total	arm	entries.	
For	contextual	fear	conditioning	test	(CFC),	on	day	1,	a	mouse	was	
placed for a total of 5 min in an isolation cubicle with an electri-
fiable	 grid	 floor	 (Coulbourn,	 USA),	with	 0.55	mA	 foot	 shocks	 for	
2	s	each	at	180	and	240	s.	On	day	2,	all	of	the	experiments	were	
performed	in	the	same	conditions	as	day	1,	without	a	foot	shock.	A	
mouse was allowed to freely explore the same chamber for 3 min, 
and	the	 freezing	behavior	was	analyzed	by	Freezeframe	software	
(Coulbourn,	USA).
4.3 | Generation of human brain cortical organoids 
from hiPSCs
AD	patient-derived	hiPSCs	(participant	no.:	CW50039)	and	healthy	
control-derived	hiPSCs	 (participant	no.:	cw50071)	were	purchased	
from	 Coriell	 Institute	 for	Medical	 Research	 (Camden,	 USA).	 Brain	
cortical organoids were generated using previously reported meth-
ods.	Briefly,	to	form	embryoid	bodies	(EBs),	suspended	iPSC	colonies	
were	 incubated	 for	48	hr	 and	 the	aggregated	EBs	were	moved	 to	
Corning	 low	attachment	plates.	After	 five	days,	 the	 floating	 sphe-
roids	were	transferred	into	neuronal	medium.	FGF2	and	EGF	were	
replaced with 100 μg/ml of BDNF and 100 μg/ml	 of	NT3	 on	 the	
twentieth day to promote neural differentiation, and the brain corti-
cal organoids were then used for the experiments.
For	details	of	methods,	see	Supporting	Information.
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